ABIVAX (EPA:ABVX) | WebDisclosure

PRESS RELEASE

published on 04/02/2024 at 08:30, 7 months 22 days ago

Abivax reports 2023 financial results and operational update
Abivax reports 2023 financial results & operational update. Raised EUR 500M, aims to finance operations till Q4 2025. Webcast on April 8, 2024

Financial Results Fundraising Abivax Webcast Operational Update
PRESS RELEASE

published on 04/02/2024 at 08:30, 7 months 22 days ago

Abivax publie ses résultats annuels 2023 et présente un point d’avancement sur l’activité
Abivax publie ses résultats annuels 2023 et présente un point d'avancement sur l'activité, démontrant une forte croissance financière et des progrès dans ses programmes cliniques

Croissance Financement Abivax Résultats Annuels 2023 Programmes Cliniques
BRIEF

published on 03/27/2024 at 18:05, 7 months 27 days ago

ABIVAX publie son nombre d’actions et de droits de vote au 29 février 2024

Euronext Paris Droits De Vote Capital Social Abivax Réglementation
BRIEF

published on 03/27/2024 at 18:05, 7 months 27 days ago

ABIVAX publishes its number of shares and voting rights as of February 29, 2024

Euronext Paris Share Capital Voting Rights Abivax Regulation
PRESS RELEASE

published on 03/27/2024 at 18:00, 7 months 27 days ago

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 29.02.24.
ABIVAX communique le nombre d'actions et de droits de vote au 29/02/2024, conformément aux règlements financiers. Abivax est une société de biotechnologie en phase clinique axée sur le développement de traitements thérapeutiques

Droits De Vote Biotechnologie Actions Abivax Traitements Thérapeutiques
BRIEF

published on 02/23/2024 at 18:00, 9 months ago

ABIVAX annonce une mise à jour sur son capital social et ses droits de vote

Droits De Vote Capital Social Biotechnologie Abivax Transparence Financière
BRIEF

published on 02/23/2024 at 18:00, 9 months ago

ABIVAX announces an update on its share capital and voting rights

Share Capital Voting Rights Biotechnology Abivax Financial Transparency
PRESS RELEASE

published on 02/23/2024 at 18:00, 9 months ago

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.01.24.
ABIVAX communique le nombre d'actions et de droits de vote au 31 janvier 2024. Abivax est une société de biotechnologie développant des traitements pour les maladies inflammatoires

Droits De Vote Biotechnologie Actions Abivax Maladies Inflammatoires
PRESS RELEASE

published on 02/13/2024 at 08:30, 9 months 11 days ago

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
Abivax to present four abstracts on obefazimod for ulcerative colitis at 19th ECCO Congress, including a sponsored symposium on emerging treatment mechanisms. Event details available on ECCO website

Abivax Obefazimod Ulcerative Colitis ECCO Congress Scientific Symposium
PRESS RELEASE

published on 02/13/2024 at 08:30, 9 months 11 days ago

Abivax annonce la présentation de quatre abstracts sur obefazimod dans la rectocolite hémorragique et l’organisation d’un symposium scientifique au 19e congrès de la ECCO
Abivax annonce la présentation de quatre abstracts sur obefazimod dans la rectocolite hémorragique et l'organisation d'un symposium scientifique au 19e congrès de la ECCO. Pour plus d'informations, visitez le stand Abivax dans le hall des exposants de l’ECCO

Abivax Obefazimod Rectocolite Hémorragique Symposium Scientifique ECCO

Published on 11/22/2024 at 23:55, 1 day 10 hours ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day 10 hours ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day 10 hours ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 1 day 10 hours ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day 11 hours ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 1 day 15 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 1 day 15 hours ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 1 day 16 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 1 day 17 hours ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 1 day 17 hours ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 17:45, 1 day 16 hours ago

IMMERSION : RFA 2023/2024
Published on 11/22/2024 at 16:15, 1 day 17 hours ago

NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/22/2024 at 14:35, 1 day 19 hours ago

Communiqué de presse Thales
Published on 11/22/2024 at 14:35, 1 day 19 hours ago

Thales Press release
Published on 11/21/2024 at 06:58, 3 days 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio

View all LES ECHOS COMFI WIRE

News